{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dalfampridine%2FPlacebo",
    "query": {
      "intervention": "Dalfampridine/Placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 38,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dalfampridine%2FPlacebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T14:56:57.838Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03578354",
      "title": "4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vestibular Migraine",
        "Migraine Disorders",
        "Vestibular Diseases"
      ],
      "interventions": [
        {
          "name": "4-aminopyridine",
          "type": "DRUG"
        },
        {
          "name": "Atenolol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-01",
      "completion_date": "2024-08",
      "has_results": false,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03578354"
    },
    {
      "nct_id": "NCT03658408",
      "title": "4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Disease"
      ],
      "interventions": [
        {
          "name": "4-aminopyridine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "45 Years to 75 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2018-10-03",
      "completion_date": "2018-10-30",
      "has_results": false,
      "last_update_posted_date": "2018-11-02",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03658408"
    },
    {
      "nct_id": "NCT00053417",
      "title": "Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)",
          "type": "DRUG"
        },
        {
          "name": "15 mg fampridine-SR (4-aminopyridine, 4-AP)",
          "type": "DRUG"
        },
        {
          "name": "20 mg fampridine-SR (4-aminopyridine, 4-AP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 206,
      "start_date": "2003-02",
      "completion_date": "2003-12",
      "has_results": true,
      "last_update_posted_date": "2011-08-04",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053417"
    },
    {
      "nct_id": "NCT01645787",
      "title": "Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "4-aminopyridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 11,
      "start_date": "2012-06-01",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01645787"
    },
    {
      "nct_id": "NCT01605825",
      "title": "A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "placebo/dalfampridine-ER",
          "type": "DRUG"
        },
        {
          "name": "dalfampridine-ER/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 83,
      "start_date": "2012-05",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2016-01-22",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Newport Beach, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605825"
    },
    {
      "nct_id": "NCT01328379",
      "title": "Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Dalfampridine-ER 5mg",
          "type": "DRUG"
        },
        {
          "name": "Dalfampridine-ER 10mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 430,
      "start_date": "2011-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2013-09-05",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 70,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 59 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01328379"
    },
    {
      "nct_id": "NCT01444300",
      "title": "Dalfampridine for Imbalance in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "Dalfampridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "20 Years to 59 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-09",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01444300"
    },
    {
      "nct_id": "NCT06003166",
      "title": "4-AP Peripheral Nerve Crossover Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Nerve Injury",
        "Crush Injury"
      ],
      "interventions": [
        {
          "name": "4-Aminopyridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 68,
      "start_date": "2025-04-21",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06003166"
    },
    {
      "nct_id": "NCT01337986",
      "title": "Ampyra for Optic Neuritis in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Optic Neuritis"
      ],
      "interventions": [
        {
          "name": "Dalfampridine/Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo/Dalfampridine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 53,
      "start_date": "2011-05",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2020-01-30",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01337986"
    },
    {
      "nct_id": "NCT04026568",
      "title": "A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Nerve Injury"
      ],
      "interventions": [
        {
          "name": "4-Aminopyridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-08-17",
      "completion_date": "2022-07-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-09-22T14:56:57.838Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04026568"
    }
  ]
}